BR0311759A - Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento - Google Patents
Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimentoInfo
- Publication number
- BR0311759A BR0311759A BR0311759-6A BR0311759A BR0311759A BR 0311759 A BR0311759 A BR 0311759A BR 0311759 A BR0311759 A BR 0311759A BR 0311759 A BR0311759 A BR 0311759A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- disease
- regurgitation
- asthma
- reflux
- Prior art date
Links
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 title abstract 3
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 3
- 206010067171 Regurgitation Diseases 0.000 title abstract 2
- 208000006673 asthma Diseases 0.000 title abstract 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 title abstract 2
- 210000000111 lower esophageal sphincter Anatomy 0.000 title abstract 2
- 230000001052 transient effect Effects 0.000 title abstract 2
- 201000008197 Laryngitis Diseases 0.000 title 1
- 208000019693 Lung disease Diseases 0.000 title 1
- 201000009243 chronic laryngitis Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000003287 optical effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000010992 reflux Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201943A SE0201943D0 (sv) | 2002-06-20 | 2002-06-20 | New use |
| PCT/US2003/016223 WO2004000316A1 (en) | 2002-06-20 | 2003-06-19 | Use of mglur5 antagonists for the treatment of gerd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311759A true BR0311759A (pt) | 2005-03-08 |
Family
ID=20288301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311759-6A BR0311759A (pt) | 2002-06-20 | 2003-06-19 | Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1513525B1 (enExample) |
| JP (2) | JP4683920B2 (enExample) |
| CN (1) | CN100430056C (enExample) |
| AT (1) | ATE395059T1 (enExample) |
| AU (1) | AU2003241585B2 (enExample) |
| BR (1) | BR0311759A (enExample) |
| CA (1) | CA2489730C (enExample) |
| CY (1) | CY1107954T1 (enExample) |
| DE (1) | DE60320990D1 (enExample) |
| DK (1) | DK1513525T3 (enExample) |
| ES (1) | ES2304510T3 (enExample) |
| IL (1) | IL165138A0 (enExample) |
| IS (1) | IS7654A (enExample) |
| MX (1) | MXPA04012659A (enExample) |
| NO (1) | NO20050154L (enExample) |
| NZ (1) | NZ536559A (enExample) |
| PL (1) | PL372186A1 (enExample) |
| PT (1) | PT1513525E (enExample) |
| RU (1) | RU2324484C2 (enExample) |
| SE (1) | SE0201943D0 (enExample) |
| SI (1) | SI1513525T1 (enExample) |
| UA (1) | UA81627C2 (enExample) |
| WO (1) | WO2004000316A1 (enExample) |
| ZA (1) | ZA200409908B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964609B2 (en) | 2002-06-20 | 2011-06-21 | Astrazeneca Ab | Use of mGluR5 antagonists for the treatment of gerd |
| SE0303418D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 1 |
| WO2005060971A1 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of reflux-related diseases |
| WO2005060961A2 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| WO2005077368A2 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| NZ548693A (en) * | 2004-02-18 | 2010-05-28 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CA2556268A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
| GB0514296D0 (en) * | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
| PT2001849E (pt) * | 2006-03-29 | 2015-02-05 | Hoffmann La Roche | Derivados de piridina e pirimidina como antagonistas de r2mglu |
| EP2272509A1 (en) | 2006-09-11 | 2011-01-12 | Novartis AG | New Uses of metabotropic glutamate receptors |
| JP2008245225A (ja) * | 2007-03-29 | 2008-10-09 | Kddi Corp | 波長パス経路決定装置、波長パス設定制御システム及びプログラム |
| WO2009024491A1 (en) * | 2007-08-20 | 2009-02-26 | F. Hoffmann-La Roche Ag | Use of mglur5 antagonists for the treatment of gerd |
| US8703809B2 (en) | 2008-06-30 | 2014-04-22 | Novartis Ag | Combination products |
| CN102573842A (zh) | 2009-07-23 | 2012-07-11 | 诺瓦提斯公司 | 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途 |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| WO2011048150A1 (en) | 2009-10-20 | 2011-04-28 | Novartis Ag | Use of 1h-quinazoline-2,4-diones |
| JP2013529622A (ja) | 2010-06-24 | 2013-07-22 | ノバルティス アーゲー | １ｈ−キナゾリン−２，４−ジオンの使用 |
| BR112013018726A2 (pt) | 2011-01-27 | 2016-10-25 | Novartis Ag | uso de ativadores de alfa 7 do receptor nicotínico de acetilcolina |
| AU2011376333A1 (en) | 2011-09-07 | 2014-03-13 | Novartis Ag | Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy |
| JP2016508159A (ja) | 2013-01-15 | 2016-03-17 | ノバルティス アーゲー | アルファ７ニコチン性アセチルコリン受容体アゴニストの使用 |
| CN105263492B (zh) | 2013-01-15 | 2018-04-10 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用 |
| MX2022005312A (es) * | 2019-11-05 | 2022-05-26 | Claes Thulin | 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1, 2,4- triazol-3-il]piridina para el uso en la prevencion y/o tratamiento de la fatiga nerviosa en un mamifero. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987004077A1 (en) * | 1986-01-03 | 1987-07-16 | The University Of Melbourne | Gastro-oesophageal reflux composition |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| JP2002515448A (ja) * | 1998-05-15 | 2002-05-28 | アフトン・コーポレーシヨン | 食道逆流病の処置法 |
| RU2144331C1 (ru) * | 1998-11-05 | 2000-01-20 | Московский НИИ уха, горла и носа | Способ лечения хронического гиперпластического ларингита |
| HUP0202757A3 (en) * | 1999-08-19 | 2006-03-28 | Nps Pharmaceuticals Inc Salt L | Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists |
| SK5212003A3 (en) * | 2000-10-02 | 2004-03-02 | Janssen Pharmaceutica Nv | Metabotropic glutamate receptor antagonists |
-
2002
- 2002-06-20 SE SE0201943A patent/SE0201943D0/xx unknown
-
2003
- 2003-06-19 DK DK03731333T patent/DK1513525T3/da active
- 2003-06-19 CN CNB038141760A patent/CN100430056C/zh not_active Expired - Fee Related
- 2003-06-19 PT PT03731333T patent/PT1513525E/pt unknown
- 2003-06-19 AU AU2003241585A patent/AU2003241585B2/en not_active Ceased
- 2003-06-19 SI SI200331220T patent/SI1513525T1/sl unknown
- 2003-06-19 EP EP03731333A patent/EP1513525B1/en not_active Expired - Lifetime
- 2003-06-19 AT AT03731333T patent/ATE395059T1/de active
- 2003-06-19 CA CA2489730A patent/CA2489730C/en not_active Expired - Fee Related
- 2003-06-19 MX MXPA04012659A patent/MXPA04012659A/es not_active Application Discontinuation
- 2003-06-19 BR BR0311759-6A patent/BR0311759A/pt not_active IP Right Cessation
- 2003-06-19 ES ES03731333T patent/ES2304510T3/es not_active Expired - Lifetime
- 2003-06-19 DE DE60320990T patent/DE60320990D1/de not_active Expired - Lifetime
- 2003-06-19 JP JP2004515703A patent/JP4683920B2/ja not_active Expired - Fee Related
- 2003-06-19 RU RU2005101411/15A patent/RU2324484C2/ru not_active IP Right Cessation
- 2003-06-19 NZ NZ536559A patent/NZ536559A/en not_active IP Right Cessation
- 2003-06-19 PL PL03372186A patent/PL372186A1/xx not_active Application Discontinuation
- 2003-06-19 WO PCT/US2003/016223 patent/WO2004000316A1/en not_active Ceased
- 2003-06-19 UA UA20041210177A patent/UA81627C2/ru unknown
-
2004
- 2004-11-10 IL IL16513804A patent/IL165138A0/xx unknown
- 2004-12-07 ZA ZA200409908A patent/ZA200409908B/en unknown
-
2005
- 2005-01-11 NO NO20050154A patent/NO20050154L/no not_active Application Discontinuation
- 2005-01-19 IS IS7654A patent/IS7654A/is unknown
-
2008
- 2008-05-21 CY CY20081100527T patent/CY1107954T1/el unknown
-
2010
- 2010-12-01 JP JP2010268162A patent/JP2011068669A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL372186A1 (en) | 2005-07-11 |
| DE60320990D1 (de) | 2008-06-26 |
| NO20050154L (no) | 2005-01-11 |
| UA81627C2 (ru) | 2008-01-25 |
| PT1513525E (pt) | 2008-06-24 |
| AU2003241585A1 (en) | 2004-01-06 |
| DK1513525T3 (da) | 2008-08-11 |
| EP1513525B1 (en) | 2008-05-14 |
| HK1075833A1 (en) | 2005-12-30 |
| ES2304510T3 (es) | 2008-10-16 |
| WO2004000316A1 (en) | 2003-12-31 |
| MXPA04012659A (es) | 2006-05-25 |
| EP1513525A1 (en) | 2005-03-16 |
| JP2006507225A (ja) | 2006-03-02 |
| JP4683920B2 (ja) | 2011-05-18 |
| CA2489730A1 (en) | 2003-12-31 |
| ZA200409908B (en) | 2006-08-30 |
| CN1662235A (zh) | 2005-08-31 |
| ATE395059T1 (de) | 2008-05-15 |
| RU2005101411A (ru) | 2005-07-10 |
| SI1513525T1 (sl) | 2008-08-31 |
| IS7654A (is) | 2005-01-19 |
| CY1107954T1 (el) | 2013-09-04 |
| SE0201943D0 (sv) | 2002-06-20 |
| JP2011068669A (ja) | 2011-04-07 |
| CA2489730C (en) | 2011-11-22 |
| IL165138A0 (en) | 2005-12-18 |
| CN100430056C (zh) | 2008-11-05 |
| NZ536559A (en) | 2007-08-31 |
| AU2003241585B2 (en) | 2009-06-25 |
| RU2324484C2 (ru) | 2008-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0311759A (pt) | Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento | |
| BR0312940A (pt) | Inibidores de quinases | |
| EA200801805A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| CY1106697T1 (el) | Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων | |
| BRPI0513565A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
| CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| MXPA05010958A (es) | Derivados indazol como inhibidores jnk. | |
| BR0214112A (pt) | Indazolilpirrolotriazinas modificadas c-5 | |
| BR0317600A (pt) | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina | |
| BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
| BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
| BR0115936A (pt) | 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
| PT1336407E (pt) | Composicao contendo um antagonista do receptor de angiotensina e um diuretico e sua utilizacao para o tratamento da hipertensao | |
| CY1106365T1 (el) | Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου | |
| SE9902267D0 (sv) | New compounds | |
| TW200604165A (en) | Novel benzyl(idene)-lactam derivatives | |
| MXPA04008460A (es) | Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista de receptor de histamina. | |
| WO2006114666A8 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
| BR0307266A (pt) | Compostos que inibem a atividade do fator xa | |
| CA2447465A1 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine for the treatment of pain | |
| DK1503764T3 (da) | 5-HT4-receptor-antagonister til behandling af hjertesvigt | |
| SE0303492D0 (sv) | New use VII |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: ASTRAZENECA AB (SE) , NPS PHARMACEUTICALS, INC. (U Free format text: SEDE DO 2O TITULAR ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070160629/RJ DE 13/11/2007. |
|
| B25A | Requested transfer of rights approved |
Owner name: ASTRAZENECA AB (SE) Free format text: TRANSFERIDO DE: NPS PHARMACEUTICALS, INC. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A., E 8A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A E 8A ANUIDADES. |